Bpifrance

Tech solution to accelerate biodiversity restoration.

Mabqi, headquartered in Grabels, France, is a biopharmaceutical company specializing in immunotherapy. It operates an antibody discovery platform, enabling the identification and development of innovative, proprietary therapeutic molecules.

Hexana is a nuclear energy company specializing in small modular reactors (SMRs). It operates sodium-cooled fast neutron reactors, integrated with high-temperature storage systems, to produce flexible electricity and process heat. The company aims to reduce nuclear waste volume through its innovative technology.

NEBULA maps 3D macromolecule using dataset-free genAI and physics, enhancing drug target discovery, which forms the basis of all new drugs.

Mirabelle is a technology-driven financial services company focused on addressing the financial needs of retirees. It specializes in offering reverse mortgage loans and life annuities, with a commitment to providing secure and informed decision-making processes. The company's core business involves advising on life annuity financing, ensuring retirees have access to guaranteed monthly income supplements, and assisting with senior housing renovations. Mirabelle's mission is to enable retirees and their families to live comfortably and securely in their homes during their golden years.

Lingua Custodia SAS is a Fintech company specializing in machine translation solutions tailored for the financial sector. Founded in 2011 and headquartered in Montigny-le-Bretonneux, France, the company initially focused on providing specialized machine translation services. It has since expanded its offerings to include a suite of Natural Language Processing (NLP) applications, such as Speech-to-Text automation, document classification, and data extraction from unstructured documents. Lingua Custodia's platform supports various document types, including fund prospectuses, annual reports, and equity research, enabling financial professionals to streamline their translation processes. The company serves a diverse clientele, including investment houses, banks, and language service providers, delivering superior quality through advanced machine learning algorithms specifically designed for the financial domain. Its innovative technology has received recognition and awards within the industry, underscoring its commitment to enhancing translation efficiency for finance-related documents.

Iadys designs, develops, and delivers robotic and AI innovations aimed at environmental preservation. The company's flagship product, the Jellyfishbot, is a robot that collects floating waste and oil in water bodies and performs underwater measurements. Iadys also offers the Mobile Oil Skimmer, which is used for oil spill response. These products are designed to access and clean hard-to-reach areas, contributing to cleaner and safer aquatic environments.

Fudzs is a pioneer in the sustainable bioeconomy, specializing in the development of eco-friendly cell bioproduction processes utilizing advanced bioreactor technology. The company focuses on the mass production of cells through innovative biomaterial engineering combined with cellular science, which enables cost-effective solutions for various industries. Fudzs aims to revolutionize the cultivated meat sector by creating affordable and high-quality meat alternatives, as well as enhancing cell therapies. Its proprietary approach to biomaterials is optimized for cell growth, significantly increasing cell amplification and density in bioreactors, thereby unlocking new market opportunities and promoting a more sustainable future in food production and healthcare.

Okomera is a biotech start-up focused on enhancing the development of precision-based cancer medicines. The company specializes in automating and streamlining individualized tumor biopsy research through innovative medical technologies. By utilizing microfluidic 3D cellular assays, Okomera's approach allows for the prediction of patient-specific responses to therapies. This is achieved by cultivating cells within thousands of microfluidic droplets and exposing them to various conditions in parallel, which accelerates the process of biologically relevant biopsy testing. Consequently, Okomera's technologies enable healthcare providers to expedite cancer treatment, ultimately improving patient outcomes.

Aura Aero is a manufacturer focused on designing and producing eco-efficient aircraft to support the decarbonization of air transport. The company develops low-carbon vehicles equipped with advanced safety features, including a whole rescue parachute system, anti-crash seats, and anti-crash fuel tanks. Their aircraft are designed with a two-seater configuration and side-by-side taildragger landing gears, aiming to enhance operational efficiency within the aeronautical industry. Through its innovative approach, Aura Aero seeks to contribute significantly to reducing the environmental impact of aviation.

Genomines focuses on sustainable mining by utilizing genetically enhanced hyperaccumulator plants to extract critical metals from soil. By leveraging synthetic biology, the company enhances the natural capacity of these plants to absorb metals, which not only allows for the recovery of valuable resources but also contributes to soil depollution and increases agricultural land availability. This approach addresses the growing demand for metals essential for clean energy technologies while mitigating the environmental and social challenges associated with traditional mining practices. Genomines aims to create a more responsible and sustainable pathway for metal extraction, aligning with global efforts to transition to greener energy solutions.

Biodol Therapeutics SAS, founded in 2015 and located in Clapiers, France, focuses on developing innovative treatments for chronic pain. The company has identified the receptor tyrosine kinase FLT3 as a critical factor in triggering and sustaining chronic neuropathic pain. Through its proprietary approach, Biodol Therapeutics develops extracellular inhibitors of the FLT3 receptor, which aim to inhibit ligand binding and thereby alleviate conditions such as allodynia, pain hypersensitivity, and spontaneous pain without disrupting normal nervous system function. Additionally, research partnerships have indicated that inhibiting FLT3 may enhance the efficacy of opioids, potentially reducing their associated risks, including addiction. This innovative work positions Biodol Therapeutics as a significant player in addressing chronic pain and contributing to solutions for the opioid crisis.

Hephaistos Pharma is a biotechnology company focused on advancing oncology treatments through innovative immunotherapy solutions. The firm develops a platform that utilizes active and non-specific immuno-stimulants to enhance the effectiveness of existing antibodies by transforming cold tumors into hot targets, which can significantly improve patient outcomes. This approach aims to address unmet medical needs in cancer treatment, enabling patients to tackle previously incurable cancers. Hephaistos Pharma is dedicated to elevating immunotherapy efficiency by stimulating immune responses, thereby offering new hope in the fight against cancer. Interested parties can access more information through an online inquiry form available on the company's website.

Magnetfab pioneers the mass-production of integrated micromagnets, driving advanced miniaturization for next-generation consumer electronics, robotics, quantum computing, and beyond.

Touch Sensity is an information technology company focused on developing sensitivity technology that enhances the interaction between objects and their environments. The company specializes in Internet of Things (IoT) and sensor technologies, creating solutions that can adapt to various sizes, shapes, and surface topologies. Its innovative approach is sensorless and non-invasive, allowing for the comprehensive capture of data related to pressure, extension, and deformation across complete surfaces. This capability enables clients to gain valuable insights by associating physical interactions with environmental factors.

Tribun Health is a company focused on transforming cancer detection through innovative diagnostic imaging software. Its solutions enable diagnostic laboratories and the pharmaceutical and biotech sectors to effectively manage, analyze, and share cellular images. By offering digital microscopy-like analysis along with macroscopic imaging capabilities, Tribun Health enhances the accuracy of diagnostics and scientific evaluations related to patient cells and tissues. The company's technology aims to streamline the workflow in laboratories, facilitating better collaboration and data sharing among healthcare professionals.

SeaBeLife Biotech SAS is a biotechnology company based in Roscoff, France, established in 2019. The company focuses on developing innovative drug candidates aimed at treating acute pathologies, particularly acute liver and renal failure. SeaBeLife's products are derived from a family of patented molecules designed to block regulated necrosis, a type of regulated cell death. By targeting two synergistic pathways involved in various acute and chronic diseases, SeaBeLife aims to establish a new standard of care for patients with significant unmet medical needs. Through its research and development efforts, the company seeks to enhance patient outcomes and reduce complications associated with serious health conditions.

Chipiron is a developer of innovative portable MRI machines that utilize advanced quantum detectors to generate three-dimensional anatomical images. By operating at ultra-low magnetic fields, these machines are designed to be lightweight and efficient, significantly reducing costs compared to traditional MRI technologies. The company's focus on employing quantum sensors enhances the capability of these portable devices for disease detection, diagnosis, and treatment monitoring, particularly for brain-related conditions. This approach aims to empower healthcare institutions to improve patient outcomes and decrease the fatality rates associated with neurological diseases.

Surge is a biotechnology company dedicated to enhancing surgical outcomes for patients. It has developed an advanced immunological model known as Surge2surgery, which predicts postoperative infections. This innovative platform integrates a single-cell analysis of the immune system conducted prior to surgery with clinical data, utilizing a proprietary machine-learning algorithm. By examining millions of immune cells from a small blood sample, Surge's technology simulates surgical trauma in a controlled environment, allowing for improved predictions and potentially better patient care.

Alice & Bob is a Paris-based company founded in 2020 that specializes in the manufacture of universal, error-free quantum computers. The company's innovative technology features self-correcting superconducting quantum bits, which allow for fault-tolerant quantum computing. This capability enables the execution of any quantum algorithm, thereby assisting industries and researchers in addressing complex challenges across various fields. By focusing on developing advanced quantum computing solutions, Alice & Bob aims to facilitate breakthroughs in solving significant problems in quantum research and industry applications.

Sequans Communications S.A. is a designer and supplier of cellular semiconductor solutions, specializing in 4G and 5G chips and modules tailored for massive, broadband, and critical Internet of Things (IoT) markets. Established in 2003 and headquartered in Paris, France, the company offers a diverse product portfolio that includes its Monarch LTE-M/NB-IoT and Calliope Cat 1 chip platforms for 5G/4G massive IoT applications, known for their low power consumption and integrated functionalities. For broadband and critical IoT applications, Sequans provides the Cassiopeia Cat 4/Cat 6 4G and high-end Taurus 5G chip platforms, which are optimized for various sectors including residential, enterprise, and industrial uses. The company serves a global market with additional offices in the United States, United Kingdom, Israel, Hong Kong, Singapore, Taiwan, South Korea, and China.

ABIONYX Pharma SA is a French biopharmaceutical company established in 2005, currently based in Labege. It specializes in the discovery and development of therapies targeting high-density lipoprotein (HDL) for treating cardiovascular and metabolic diseases. The company's primary focus is on developing HDL mimetics to rapidly regress atherosclerotic plaque in high-risk patients. Its lead product candidate, CER-001, is a Phase II clinical trial asset designed to mimic the properties of pre-beta HDL for treating post-acute coronary syndrome patients and familial primary hypoalphalipoproteinemia patients. Additionally, ABIONYX Pharma has another drug candidate, CER-209, in Phase I trials for metabolic diseases and liver-related conditions such as atherosclerosis and non-alcoholic steato-hepatitis.

Sunver is a start-up offering the first fully plug & play B2B SaaS solution for tourism establishments and restaurants, enabling them to create and configure a Guest App in just a few minutes.

UniFox is an AI-driven ecosystem focused on sustainable investment, integrating green energy and eco-responsible technologies for individual and institutional investors. Its structure encompasses four divisions: B2C, B2B, Capital Ventures, and Green DeFi. Central to its offerings is VulpesAI, a multi-modal AI engine that employs market data, sentiment analysis, and ESG (Environmental, Social, Governance) criteria to create optimized investment strategies while operating on renewable energy sources. For individual users, UniFox provides AI-powered portfolio management that delivers comprehensive market insights and risk management, allowing for personalized investment strategies. On the institutional side, it offers advanced data access and metrics for large-scale investments in green projects. The Green DeFi division focuses on financing eco-friendly technology initiatives through decentralized finance, utilizing eco-taxed products and tokens to support sustainable ventures. Overall, UniFox seeks to enhance the accessibility of investment opportunities while promoting environmental responsibility and addressing challenges faced by novice traders in the market.

I.Ceram SA is a France-based company that specializes in the design, manufacture, and marketing of alumina bio-ceramic implants for various joints of the human body. Founded in 2005 and headquartered in Limoges, I.Ceram offers a range of implants for the ankle, knee, hip, spine, shoulder, wrist, skull, tibia, and foot, as well as osteosynthesis products. The company operates both domestically and internationally, emphasizing innovation and high-quality materials in its product offerings. I.Ceram is a subsidiary of Investissement Développement.

Novacium operates as an innovative start-up that specializes in the next generation material development.

Okomera is a biotech start-up focused on enhancing the development of precision-based cancer medicines. The company specializes in automating and streamlining individualized tumor biopsy research through innovative medical technologies. By utilizing microfluidic 3D cellular assays, Okomera's approach allows for the prediction of patient-specific responses to therapies. This is achieved by cultivating cells within thousands of microfluidic droplets and exposing them to various conditions in parallel, which accelerates the process of biologically relevant biopsy testing. Consequently, Okomera's technologies enable healthcare providers to expedite cancer treatment, ultimately improving patient outcomes.

Huvy specializes in developing a skin cancer screening application that utilizes artificial intelligence to enhance dermatological treatment pathways. The application aims to identify cancer risks and provide essential medical information in real-time. By facilitating dermatological screening, Huvy's technology enables access to initial diagnostic orientation for populations in areas with limited medical resources. This approach allows for timely care and intervention when there is a suspicion of skin cancer, ultimately improving health outcomes for underserved communities.

eyeGauge is a Paris-based deep tech start-up dedicated to transforming the maritime industry by facilitating the decarbonization of maritime transportation. The company aims to help shipping companies meet International Maritime Organization targets by reducing greenhouse gas emissions by at least 50% by 2050. To comply with decarbonization regulations, ship owners must accurately measure and report emissions after every voyage. However, 85% of the world's fleet currently relies on manual data collection, which is often unreliable and difficult to analyze. eyeGauge addresses this challenge by offering an innovative, automated solution that collects data from onboard systems in a contactless and non-invasive manner. This technology generates consistent and comparable data, creating a digital model of a vessel's equipment and machinery. By providing insights into operations, eyeGauge enables shipping companies to identify optimization opportunities and enhance efficiency, ultimately supporting their efforts to reduce emissions and comply with regulations.

Astraveus is transforming cell and gene therapy (CGT) manufacturing through its Lakhesys™ platform, an innovative cell foundry that leverages deep process optimization and microfluidic bioprocessors. This technology allows for the production of personalized biological therapies with minimal infrastructure requirements, ultimately reducing costs and addressing logistical challenges in the industry. By automating autologous bioproduction, the platform enhances the efficiency of transforming cells into therapeutic agents, enabling healthcare providers to scale the development and manufacturing of CGT solutions. Astraveus aims to improve patient access to these vital therapies while minimizing environmental impact.

Injectpower specializes in developing energy storage technologies and micro-batteries tailored for medical implants. Their core product is a small, solid-state battery that powers implantable devices, enabling them to function as sensors or actuators for extended periods without the need for recharging. With over 16 years of research and 40 patents, Injectpower's batteries are manufactured using a proven semiconductor supply chain, ensuring high reliability. The company's innovative solutions include batteries for devices that monitor intraocular pressure in glaucoma patients and intracranial pressure and fluid flow, allowing physicians to remotely monitor and diagnose conditions more effectively.

F&B advertising webapp

Spark Cleantech is a pioneering company developing a plasma technology to convert greenhouse gases into hydrogen fuel. Its core process, called plasmolysis, uses cold pulsed plasma discharges to break down methane or carbon dioxide and methane mixtures, producing hydrogen, solid carbon, and carbon monoxide. This on-site hydrogen production offers a competitive, carbon-neutral alternative to fossil fuels, enabling the decarbonization of industrial heat and the transition to clean transportation.

Global Bioenergies SA specializes in developing a biological process that converts renewable resources into isobutene, a crucial petrochemical building block used in fuels, plastics, organic glass, and elastomers. The company, based in Evry, France, is notable for being one of the few globally and the only one in Europe focusing on this innovative fermentation technology. It operates an industrial pilot plant and is nearing the completion of a demonstration plant in Germany, alongside preparing for its first full-scale production facility in collaboration with Cristal Union, known as IBN-One. In addition to isobutene, Global Bioenergies has expanded its capabilities to include the production of propylene and butadiene, both vital components in the petrochemical sector. The company was founded in 2008 and continues to enhance the efficiency of its processes while offering engineering services related to gas fermentation.

Circul'Egg specializes in recycling eggshells from various companies, converting them into two primary products: calcium carbonate powder and shell membrane powder. By promoting sustainable practices within the circular economy, Circul'Egg addresses the growing demand for eco-friendly ingredients in the animal feed, nutraceutical, and cosmetics markets. Its offerings are designed to meet the needs of various stakeholders, including those in pet food, farm animal feed, dietary supplements, and cosmetic industries. The company emphasizes the natural, biobased, and vegetarian aspects of its products, ensuring they are both environmentally friendly and rich in valuable minerals and biomolecules. Established in Paris, Ile-de-France, France, Circul'Egg plays a crucial role in transforming waste into valuable resources for multiple sectors.

Remixt is a leading Diversity, Equity and Inclusion tech platform dedicated to preventing key HR risks caused by harassment and discrimination. The company is headquartered in Paris, France, with employees in Paris, San Francisco, Toulouse and Annecy. Remixt’s clients include global corporations Heineken, Société Générale, Accenture, Groupe BPCE-Natixis and Hexagon. For more information: http://www.remixt.co

ERAMET is a world leader in alloy metals, including manganese and nickel, and high-end metallurgy. ERAMET also develops activities with high growth potential, such as mineralized sands (titanium dioxide and zircon), lithium and recycling. The Group employs approximately 13,000 people in 20 countries.

Toopi Organics SAS is a biotechnology company based in Langon, France, that specializes in the collection and upcycling of human urine to create biostimulants for agriculture. Founded in 2019, the company develops products like Arbop and Vitip, which support plant growth by serving as natural alternatives to chemical fertilizers. Toopi Organics employs microbiological technology to enhance and enrich human urine, providing an environmentally friendly solution for the agricultural community. By transforming waste into valuable resources, the company aims to offer economical and efficient options for sustainable farming practices.

Phagos is a biotechnology company focused on developing personalized bacteriophage solutions as a sustainable alternative to traditional antibiotics. The company operates a research platform that creates customizable drugs aimed at replacing antibiotics in animal farming. By harnessing bacteriophages, which are natural predators of bacteria, Phagos seeks to provide an effective means to combat incurable and deadly infectious diseases. This innovative approach aligns with the growing need for alternatives to antibiotics in both human and veterinary medicine, addressing health challenges while promoting sustainable practices in agriculture.

Aviwell is focused on creating healthy, natural, and sustainable solutions aimed at enhancing animal health and growth, thereby contributing to global nourishment. The company operates a microbiota-based discovery platform that leverages artificial intelligence and machine learning to bridge digital and life sciences. By developing innovative food products, Aviwell seeks to provide valuable insights into animal health, growth, and performance, ultimately supporting the agri-food industry in its efforts to sustainably meet the needs of a growing population.

Deemea is a developer of a digital medical assistance platform tailored for clinical research and the analysis of real-life data. The company's AI-driven platform assists clinical research operators by streamlining the imaging data journey, enhancing efficiency and reliability. It utilizes artificial intelligence to identify suitable databases, expedites contractual and regulatory processes, and simplifies external model validation. Additionally, Deemea's platform optimizes responses to internal and external requests while valorizing real-world data and clinical studies. Through these capabilities, Deemea supports clients in accelerating the development and deployment of innovative projects that leverage AI tools specific to the valorization of medical data.

Genomines focuses on sustainable mining by utilizing genetically enhanced hyperaccumulator plants to extract critical metals from soil. By leveraging synthetic biology, the company enhances the natural capacity of these plants to absorb metals, which not only allows for the recovery of valuable resources but also contributes to soil depollution and increases agricultural land availability. This approach addresses the growing demand for metals essential for clean energy technologies while mitigating the environmental and social challenges associated with traditional mining practices. Genomines aims to create a more responsible and sustainable pathway for metal extraction, aligning with global efforts to transition to greener energy solutions.

AlgoTherapeutix is a biotechnology company focused on developing topical treatments for complex pain conditions, particularly those that are difficult to treat and lack proven therapies. The organization targets damaged nerve fibers in the skin, aiming to provide pain relief without the systemic side effects associated with oral medications. Currently, AlgoTherapeutix's lead product, ATX01, has received FDA approval to enter Phase 2 clinical trials for chemotherapy-induced peripheral neuropathy, a painful condition resulting from cancer treatment. Additionally, the company is exploring the potential of its treatments for erythromelalgia, a rare and debilitating disorder characterized by severe pain. Through its innovative approach, AlgoTherapeutix seeks to address the specific needs of patients suffering from these challenging conditions.

Oneleaf is a startup focused on making hypnosis more accessible to individuals seeking personal improvement. The company has developed a self-hypnosis app that offers various programs aimed at addressing issues such as smoking cessation, anxiety reduction, and weight loss. By providing expert-guided digital resources, Oneleaf aims to assist users in overcoming detrimental habits and enhancing their overall well-being. The overarching goal of the company is to empower a billion people to achieve their best selves through self-hypnosis.

NFL Biosciences is a biotechnology company focused on developing solutions for tobacco addiction. The company specializes in researching and creating medicines that utilize both botanical and pharmaceutical agents to assist smokers in their efforts to quit. Its primary product, NFL-101, is a clinically developed botanical drug designed to target smoking addiction. NFL-101 contains a minimal amount of nicotine and is formulated from well-characterized natural tobacco leaf proteins, offering a novel approach to support individuals in overcoming their dependence on tobacco.

Shortcut supports CGPs and enables automation of emailing, invitations and customer communications.

Chipiron is a developer of innovative portable MRI machines that utilize advanced quantum detectors to generate three-dimensional anatomical images. By operating at ultra-low magnetic fields, these machines are designed to be lightweight and efficient, significantly reducing costs compared to traditional MRI technologies. The company's focus on employing quantum sensors enhances the capability of these portable devices for disease detection, diagnosis, and treatment monitoring, particularly for brain-related conditions. This approach aims to empower healthcare institutions to improve patient outcomes and decrease the fatality rates associated with neurological diseases.

Centralize and automate all possible customer-centric activities with external accounts. Involve your customers or suppliers directly in the platform. Part of AWS accelerator program and received the status of a Jeune Entreprise Universitaire.

Phagos is a biotechnology company focused on developing personalized bacteriophage solutions as a sustainable alternative to traditional antibiotics. The company operates a research platform that creates customizable drugs aimed at replacing antibiotics in animal farming. By harnessing bacteriophages, which are natural predators of bacteria, Phagos seeks to provide an effective means to combat incurable and deadly infectious diseases. This innovative approach aligns with the growing need for alternatives to antibiotics in both human and veterinary medicine, addressing health challenges while promoting sustainable practices in agriculture.

Osivax is a company focused on developing immunotherapy vaccines aimed at treating infectious diseases. Its innovative vaccines enhance the uptake into dendritic cells and boost the immunogenicity of natural proteins, which triggers a more effective immune response, particularly through significant CD8 T cell activation. This technology is designed to serve as a universal vaccine, targeting not only existing but also emerging coronavirus infections, as well as other globally impactful infectious diseases. In addition to infectious diseases, Osivax's vaccines also support cancer treatment, providing medical practitioners with advanced tools to treat a range of serious health conditions effectively.

Ex9 specializes in providing unmanned transport solutions for logistics operators, focusing on automating the movement of trailers within closed environments such as warehouses, distribution hubs, and manufacturing plants. The company deploys a fleet of eco-friendly, cost-effective robot-tractors designed to enhance cross-dock shunting operations. This service allows for continuous 24/7 operations, leading to significant reductions in operational costs, carbon emissions, and safety incidents. Ex9 aims to improve operational performance by 30% while achieving a remarkable reduction in CO2 emissions by nearly 90% in the global supply chain. Through its automation services, Ex9 addresses unsafe, time-consuming, and low-value tasks in industrial transport, ultimately enhancing productivity and efficiency for its clients.

Ribonexus is a biotechnology company dedicated to developing innovative therapies aimed at treating cancer, particularly melanoma. The company is focused on creating a pipeline of small molecules that target the eukaryotic translation Initiation Factor-4A (eIF4A), which plays a significant role in various solid and hematologic cancers. This target is particularly relevant for addressing resistance to existing treatments, which often diminishes the effectiveness of targeted therapies. Ribonexus aims to produce drugs that can restore sensitivity to these therapies in patients who have developed resistance, thereby improving treatment outcomes in oncology.

SeaBeLife Biotech SAS is a biotechnology company based in Roscoff, France, established in 2019. The company focuses on developing innovative drug candidates aimed at treating acute pathologies, particularly acute liver and renal failure. SeaBeLife's products are derived from a family of patented molecules designed to block regulated necrosis, a type of regulated cell death. By targeting two synergistic pathways involved in various acute and chronic diseases, SeaBeLife aims to establish a new standard of care for patients with significant unmet medical needs. Through its research and development efforts, the company seeks to enhance patient outcomes and reduce complications associated with serious health conditions.

Susu is a health tech company focused on providing accessible and affordable healthcare services to families in the African diaspora. The company offers a comprehensive range of services, including preventive care, medical treatments, chronic disease management, and authentic medications. By delivering health bundle services through its platform, Susu aims to facilitate long-term health support for patients, ensuring effective monitoring of various health conditions such as pregnancy and chronic diseases. This approach enables individuals to access quality healthcare services and insurance, promoting overall well-being within the communities it serves.

1 in 3 travellers extend their stay thanks to remote work. Improve the profitability of your space by becoming a remote work hub. Since 2020, more than 100 spaces have trusted Desk.

VistaCare is a French company specializing in the development, manufacturing, and distribution of medical devices designed for the treatment of acute and chronic wounds. The company focuses on innovative, non-contact treatment methods that operate in a controlled environment. Their technology addresses critical aspects of wound care, including the reduction of nosocomial risks, visual monitoring of wound progression, and tailored medical protocols based on the specific type and stage of each wound. By enhancing the quality of life for patients and streamlining the care process for caregivers, VistaCare aims to significantly reduce treatment times and hospital stays, offering a more effective solution for complex wounds that are challenging to manage with conventional therapies.

Diaccurate is a biotechnology company based in Paris, France, that focuses on researching and developing treatments for various diseases, including HIV infection and several types of cancer. Founded in 2012, the company targets conditions such as endocrine-resistant metastatic breast tumors, glioblastoma, and refractory acute myeloid leukemia. Diaccurate is dedicated to exploring innovative therapeutic approaches in oncology, aiming to provide effective solutions for patients facing these challenging and often incurable diseases.

Pherecydes Pharma SA is a biotechnology company based in Romainville, France, established in 2006. It specializes in the research and development of lytic bacteriophages, which are natural predators of bacteria, for therapeutic and diagnostic applications, particularly in addressing antibiotic resistance. The company has developed several banks of bacteriophages, including a collection targeting Escherichia coli. Pherecydes Pharma is engaged in innovative approaches to personalized phage therapy, aiming to treat bacterial infections by launching multicenter European trials, such as those evaluating phage therapy for infected burn wounds. This therapeutic strategy allows for the detection and treatment of a wide range of bacterial infections, including multi-resistant and emergent strains, without affecting human cells.

Fysali breaks the taboo by providing remote, non-invasive bladder monitoring. They offer superior clinical accuracy, an exceptional patient experience, and a lower cost of care. They offer remote and noninvasive bladder monitoring services.

Echoliv is a medical technology company specializing in artificial intelligence solutions for abdominal ultrasound. The company develops software designed to assist radiologists and hepatologists in early-stage screening for hepatocellular carcinoma, the most common type of liver cancer. Echoliv's flagship product, Ultraliv, employs advanced algorithms to identify nodules that may be overlooked by practitioners, enhancing diagnostic accuracy and improving patient care. By integrating AI into the ultrasound process, Echoliv aims to support healthcare professionals in delivering timely and effective treatment for liver cancer.

Luos is a developer of an open-source architecture aimed at enhancing the design, testing, and deployment of embedded applications. The company's innovative software facilitates the use of microservices in embedded systems by integrating all components and functions of electronic devices into a cohesive system image. This approach allows for the creation of drivers and embedded applications through a straightforward embedded C/C++ code API. By streamlining the development process, Luos enables developers and CTOs to efficiently design and implement embedded solutions, making hardware development as agile as software.

Deemea is a developer of a digital medical assistance platform tailored for clinical research and the analysis of real-life data. The company's AI-driven platform assists clinical research operators by streamlining the imaging data journey, enhancing efficiency and reliability. It utilizes artificial intelligence to identify suitable databases, expedites contractual and regulatory processes, and simplifies external model validation. Additionally, Deemea's platform optimizes responses to internal and external requests while valorizing real-world data and clinical studies. Through these capabilities, Deemea supports clients in accelerating the development and deployment of innovative projects that leverage AI tools specific to the valorization of medical data.

Adeunis designs, manufactures, and markets connected objects and Internet of Things (IoT) solutions for various sectors, including smart buildings, industrial optimization, and connected agriculture. The company offers a range of products, such as radio frequency transmission modules, wireless transmission systems, and telemetry systems, tailored to meet the specific needs of its customers. Adeunis also provides services like on-site radio mapping, deployment, training, and data processing to support the management of buildings and infrastructure. Based in Crolles, France, the company focuses on creating customized radio solutions and ready-to-use systems that enhance connectivity and efficiency across multiple applications.

Alkion BioInnovations, established in March 2017, focuses on developing innovative cannabinoid and pharmaceutical active pharmaceutical ingredient (API) production through large-scale plant tissue culture. The company utilizes proprietary semi-industrial technologies to produce natural plant active ingredients for pharmaceutical applications, aiming to create disruptive nutrition, non-cosmetic oil, and agrochemical products for both the pharmaceutical and agri-food sectors. In addition to its work in cannabinoid production, Alkion is also developing a novel plant-based high-intensity protein sweetener as a sugar replacement. The company has received multiple R&D grants and awards, including those from I-lab, I-Nov, and the European Innovation Council, recognizing its contributions to biotechnology and innovation.

C12 Quantum Electronics is a company based in Paris, Ile-de-France, France, founded in 2019 by Pierre and Matthieu Desjardins. The company focuses on developing reliable quantum processors utilizing carbon nanotubes, which significantly reduce error rates. This technology positions C12 Quantum Electronics as a strong candidate for noisy intermediate-scale quantum applications. In addition to building quantum computers, the company also engages in developing and accelerating experiments related to information processing systems, allowing industrial clients to leverage intermediate-scale quantum applications for enhanced computing capabilities.

Biophytis SA is a clinical-stage biotechnology company based in Paris, France, dedicated to developing therapeutics that aim to slow degenerative processes linked to aging and enhance functional outcomes for patients with age-related diseases. The company focuses on activating key biological resilience pathways to mitigate the effects of various biological and environmental stresses that contribute to these conditions. Biophytis has two primary drug candidates: Sarconeos (BIO101), an orally administered small molecule being developed for neuromuscular diseases such as sarcopenia and Duchenne muscular dystrophy, and Macuneos (BIO201), also an orally administered small molecule targeting retinal diseases like dry age-related macular degeneration and Stargardt disease. The company has established a collaboration agreement with AFM-Telethon for the development of Sarconeos. Founded in 2006, Biophytis aims to become a leader in aging science by providing innovative therapies to address the needs of patients with limited treatment options.

OncoDiag is a French biotechnology company located in Normandy, dedicated to creating non-invasive diagnostic tests aimed at the early detection of cancers. Its flagship product, the Urotest, is a urine test approved for the diagnosis and monitoring of bladder cancer. In addition to the Urotest, OncoDiag is developing Colodiag, a test focused on the early identification of colorectal cancer, and other diagnostic tools, including a tissue-based test for predicting non-evolutive localized prostate cancer. Through its innovative testing kits, OncoDiag aims to enhance cancer diagnostics, allowing healthcare professionals to provide timely and effective patient care.

Luos is a developer of an open-source architecture aimed at enhancing the design, testing, and deployment of embedded applications. The company's innovative software facilitates the use of microservices in embedded systems by integrating all components and functions of electronic devices into a cohesive system image. This approach allows for the creation of drivers and embedded applications through a straightforward embedded C/C++ code API. By streamlining the development process, Luos enables developers and CTOs to efficiently design and implement embedded solutions, making hardware development as agile as software.

Fysali breaks the taboo by providing remote, non-invasive bladder monitoring. They offer superior clinical accuracy, an exceptional patient experience, and a lower cost of care. They offer remote and noninvasive bladder monitoring services.

Bybr is an online platform designed to enhance local commerce by connecting consumers with their preferred brands in a personalized manner. The company focuses on bringing local brands online, providing customers with direct access to official channels while unifying various commercial touchpoints. Bybr employs innovative technologies, including a universal scanner that recognizes logos, barcodes, and QR codes, facilitating seamless interactions between customers and businesses. Its 1Scan to connect solution simplifies the engagement process, allowing users to connect with brands effortlessly. Additionally, Bybr operates a marketplace that links influential creators with brands, enabling effective collaboration for marketing campaigns across multiple media channels. This approach aims to redefine how local commerce meets the evolving expectations of consumers.

OSE Immunotherapeutics SA is a clinical-stage biotechnology company based in Nantes, France, specializing in the development of innovative immunotherapies aimed at immune activation and regulation, particularly in the areas of immuno-oncology and autoimmune diseases. The company's product portfolio includes Tedopi, which is in Phase III clinical trials for lung cancer and Phase II for pancreatic cancer; BI 765063, currently in Phase I trials for solid tumors; and OSE-703, a humanized monoclonal antibody in preclinical development for various cancers. Additionally, OSE Immunotherapeutics is advancing FR104, which is in Phase I trials for rheumatoid arthritis, and OSE-127, a humanized monoclonal antibody in Phase I trials for inflammatory autoimmune diseases. The company collaborates with notable partners such as GERCOR, Memorial Sloan Kettering Cancer Center, Boehringer Ingelheim, Servier, and HalioDx. OSE Immunotherapeutics was previously known as OSE Pharma SA before its name change in May 2016.

Multiwave Imaging is a leading company specializing in the design of metamaterial antennas for Magnetic Resonance Imaging (MRI) and Positron Emission Tomography (PET) systems. Established in March 2015 and headquartered in Geneva, Switzerland, with a research and development facility in France, Multiwave focuses on developing innovative medical imaging devices. The company aims to enhance imaging quality in MRI, ultimately aiding in the treatment of neurological conditions. In addition to its core imaging technologies, Multiwave employs advanced quantitative portfolio analysis and sensor technologies to support retailers in their purchasing strategies, thereby maximizing profits. Through these initiatives, Multiwave Imaging seeks to advance the field of medical imaging while addressing critical healthcare needs.

Osivax is a company focused on developing immunotherapy vaccines aimed at treating infectious diseases. Its innovative vaccines enhance the uptake into dendritic cells and boost the immunogenicity of natural proteins, which triggers a more effective immune response, particularly through significant CD8 T cell activation. This technology is designed to serve as a universal vaccine, targeting not only existing but also emerging coronavirus infections, as well as other globally impactful infectious diseases. In addition to infectious diseases, Osivax's vaccines also support cancer treatment, providing medical practitioners with advanced tools to treat a range of serious health conditions effectively.

Xenothera is a biotechnology company focused on developing advanced immunological treatments through its innovative xenotherapy platform. The company specializes in creating hyperimmune polyclonal sera, which enhances passive immunotherapy for various medical applications, including immunomodulation and infectious diseases. Leveraging its expertise in animal genetics and immunology, Xenothera streamlines the development process by controlling all aspects, from the selection of immunogens to the purification of immunoglobulins. This comprehensive approach allows for accelerated market authorization, positioning Xenothera as a leader in transforming immunotherapeutic solutions for the medical community.

Quantum Surgical is a company focused on enhancing the treatment of liver cancer through minimally invasive procedures. They develop surgical robotics that provide intelligent tools for advanced percutaneous ablation therapy, which is designed to improve patient outcomes and safety in interventional oncology. By democratizing access to these innovative treatment options, Quantum Surgical aims to enable healthcare providers to more effectively cure patients and enhance their quality of life.

Multiwave Imaging is a leading company specializing in the design of metamaterial antennas for Magnetic Resonance Imaging (MRI) and Positron Emission Tomography (PET) systems. Established in March 2015 and headquartered in Geneva, Switzerland, with a research and development facility in France, Multiwave focuses on developing innovative medical imaging devices. The company aims to enhance imaging quality in MRI, ultimately aiding in the treatment of neurological conditions. In addition to its core imaging technologies, Multiwave employs advanced quantitative portfolio analysis and sensor technologies to support retailers in their purchasing strategies, thereby maximizing profits. Through these initiatives, Multiwave Imaging seeks to advance the field of medical imaging while addressing critical healthcare needs.

Vulkam SAS is a microtechnology company based in Saint-Martin-d'Hères, France, that specializes in the design, development, and production of amorphous metal parts. Founded in 2017, Vulkam utilizes biocompatible amorphous metal alloys primarily composed of materials such as zirconium, copper, hafnium, nickel, and titanium. The company's innovative products find applications across various industries, including aerospace, automotive, biomedical, cryogenic, watches, jewellery, and micro components. Vulkam's focus on creating micromechanical parts that are significantly smaller yet maintain strength and functionality sets a new standard in metallurgy and metal processing, positioning the company as a leader in the development of advanced metal technologies.

KAPTREK is the first French & European proprietary HW / SW platform declined on several markets : Outdoor sports, Industry 4.0, E-Mobility, Health & Care, Army, Sportech. KAPTREK is an all in one electronic product, allowing customized devs.

TreeFrog Therapeutics is a stem cell company based in Pessac, France, founded in 2018. It focuses on researching and producing scalable stem cell cultivation for cGMP cell therapy manufacturing. The company has developed C-Stem, a proprietary technology platform that offers an end-to-end 3D scalable solution, aimed at securing cell production and quality. This innovative approach is designed to expedite clinical development and facilitate market access for cell therapies. By addressing critical manufacturing challenges, TreeFrog Therapeutics aims to significantly reduce treatment costs, making advanced cell therapies more accessible to patients.

Exeliom is a clinical-stage biopharmaceutical company based in Dijon, France, focused on developing innovative microbial therapies that utilize commensal bacteria as therapeutic agents. Founded in 2016, Exeliom aims to unlock the therapeutic potential of gut microbiota to enhance health and longevity. The company specializes in creating a new class of medicines known as Live Biotherapeutics, which are designed to deliver microbiome-based immunotherapy for conditions such as inflammatory bowel diseases and cancer, with an initial focus on Crohn's Disease. By harnessing the role of microbiota in the immune system, Exeliom strives to provide patients with advanced treatments that improve their quality of life.

ImCheck Therapeutics SAS is a biopharmaceutical company based in Marseille, France, founded in 2015. The company specializes in the development of immunotherapeutics aimed at addressing severe unmet medical needs, primarily in the field of immuno-oncology. ImCheck focuses on creating immuno-modulatory antibodies that target members of the butyrophilin super-family of checkpoint molecules, specifically engaging γ9δ2 T cells. Its research and development efforts are directed toward treating various cancers, including breast, gastric, and ovarian cancers, as well as other immune-related diseases. The company's innovative approach positions it at the forefront of next-generation immunotherapy solutions for patients suffering from solid tumors.

Peculium is a company based in Nanterre, France, that has been focused on providing advanced wealth management services specifically for digital assets since its inception in 2017. The firm has developed a cryptocurrency savings management system that caters to clients looking for sophisticated investment solutions in the rapidly evolving digital asset landscape. By leveraging innovative technology, Peculium aims to enhance the savings and investment experience for individuals and entities involved in cryptocurrencies.

Skipper NDT specializes in contactless magnetic inspection technology aimed at enhancing the safety and efficiency of oil and gas pipelines. The company employs a high-precision magnetic inspection system combined with advanced algorithms to locate and map buried steel pipelines, effectively identifying risk zones and detecting anomalies in metallic structures. This innovative approach allows pipeline operators to optimize maintenance costs while addressing safety and environmental challenges associated with non-scraping pipelines. Additionally, Skipper NDT offers a UAV-based pipeline mapping service that provides centimeter-level precision, ensuring access to remote locations while improving overall operational safety standards.

TreeFrog Therapeutics is a stem cell company based in Pessac, France, founded in 2018. It focuses on researching and producing scalable stem cell cultivation for cGMP cell therapy manufacturing. The company has developed C-Stem, a proprietary technology platform that offers an end-to-end 3D scalable solution, aimed at securing cell production and quality. This innovative approach is designed to expedite clinical development and facilitate market access for cell therapies. By addressing critical manufacturing challenges, TreeFrog Therapeutics aims to significantly reduce treatment costs, making advanced cell therapies more accessible to patients.

Alkion BioInnovations, established in March 2017, focuses on developing innovative cannabinoid and pharmaceutical active pharmaceutical ingredient (API) production through large-scale plant tissue culture. The company utilizes proprietary semi-industrial technologies to produce natural plant active ingredients for pharmaceutical applications, aiming to create disruptive nutrition, non-cosmetic oil, and agrochemical products for both the pharmaceutical and agri-food sectors. In addition to its work in cannabinoid production, Alkion is also developing a novel plant-based high-intensity protein sweetener as a sugar replacement. The company has received multiple R&D grants and awards, including those from I-lab, I-Nov, and the European Innovation Council, recognizing its contributions to biotechnology and innovation.

Founded in 2018 by four ex-Airbus engineers: Jean-Christophe Lambert, Thibault Baldivia, Clément Dinel and Benoît Ferran, Ascendance is an industrial start-up with a mission to decarbonise aviation. Based in the heart of Toulouse, the European capital of aviation, it has developed and markets two products: an innovative hybrid-electric propulsion system ‘Sterna’, and a hybrid-electic vertical take-off and landing (VTOL) aircraft powered by Sterna technology, ‘Atea’.

Capte is a technology company that specializes in developing and integrating Internet of Things (IoT) solutions for various industries, with a focus on transportation and marine sectors. The company's core business involves creating predictive monitoring and fleet management technologies that enable real-time telemetry, vehicle diagnostics, and predictive maintenance. By leveraging these solutions, Capte helps transit agencies and fleet operators reduce vehicle downtime, optimize performance, and lower operational costs, ultimately facilitating the transition towards more efficient and sustainable transportation systems.

DNA Script SAS, established in 2014 and headquartered in Paris, France, specializes in synthetic biology tools. The company's core product, SYNTAX, is a revolutionary benchtop DNA printer that uses enzymatic technology to rapidly produce synthetic oligonucleotides, genes, pathways, and genomes. This innovative approach empowers life science researchers and labs to print their own synthetic DNA, enhancing workflow control and accelerating access to results, thereby advancing breakthroughs in life science and human health.

DNA Script SAS, established in 2014 and headquartered in Paris, France, specializes in synthetic biology tools. The company's core product, SYNTAX, is a revolutionary benchtop DNA printer that uses enzymatic technology to rapidly produce synthetic oligonucleotides, genes, pathways, and genomes. This innovative approach empowers life science researchers and labs to print their own synthetic DNA, enhancing workflow control and accelerating access to results, thereby advancing breakthroughs in life science and human health.

Surfact'Green is a company that specializes in the development and production of patented ecological surfactants derived from agro-resources such as algae and sugar beet co-products. Established as a business unit in 2011 at the Rennes National School of Chemistry, it builds on over a decade of research conducted by the Organic and Supramolecular Chemistry team. The company focuses on creating green chemistry solutions that replace products derived from petrochemistry with eco-compatible, biodegradable alternatives. Surfact'Green's surfactants are formulated to be solvent-free, sulfate-free, and readily biodegradable, allowing businesses to reduce their environmental and human health impacts. The company collaborates with various public and private laboratories, as well as industrial partners, to advance its innovations in sustainable surfactant production.

Eversend SAS, founded in 2017 and based in Paris, France, offers a multi-currency e-wallet application that enables users to send and receive money, buy cryptocurrency, create virtual cards, and purchase airtime. The platform leverages blockchain technology to provide a digital payment gateway, facilitating electronic money transfers to bank accounts and mobile payments while minimizing costs associated with fees and foreign exchange. In addition to its current services, Eversend plans to expand its offerings to include personal loans, savings, group savings, merchant payments, and investment options. The company aims to grow its presence in Nigeria, Francophone Africa, and Europe while utilizing funds for product development, user acquisition, and regulatory compliance.

OSE Immunotherapeutics SA is a clinical-stage biotechnology company based in Nantes, France, specializing in the development of innovative immunotherapies aimed at immune activation and regulation, particularly in the areas of immuno-oncology and autoimmune diseases. The company's product portfolio includes Tedopi, which is in Phase III clinical trials for lung cancer and Phase II for pancreatic cancer; BI 765063, currently in Phase I trials for solid tumors; and OSE-703, a humanized monoclonal antibody in preclinical development for various cancers. Additionally, OSE Immunotherapeutics is advancing FR104, which is in Phase I trials for rheumatoid arthritis, and OSE-127, a humanized monoclonal antibody in Phase I trials for inflammatory autoimmune diseases. The company collaborates with notable partners such as GERCOR, Memorial Sloan Kettering Cancer Center, Boehringer Ingelheim, Servier, and HalioDx. OSE Immunotherapeutics was previously known as OSE Pharma SA before its name change in May 2016.

Internest develops a precise positioning system tailored for rotating winged vehicles, such as drones and helicopters. The system features a local landing component that integrates both firmware and hardware, offering reliable and accurate positioning data regardless of visibility, weather, or environmental conditions. This technology is particularly beneficial for security, military, and maritime sectors, enhancing the operational safety of aerial vehicles during critical missions. By improving flight safety, Internest's solutions support various industries in effectively managing their aerial operations.

Internest develops a precise positioning system tailored for rotating winged vehicles, such as drones and helicopters. The system features a local landing component that integrates both firmware and hardware, offering reliable and accurate positioning data regardless of visibility, weather, or environmental conditions. This technology is particularly beneficial for security, military, and maritime sectors, enhancing the operational safety of aerial vehicles during critical missions. By improving flight safety, Internest's solutions support various industries in effectively managing their aerial operations.

VeriCampus specializes in enhancing student support for colleges and universities through the use of artificial intelligence. The company develops AI-powered chatbots, known as 'Campus Assistants,' which are designed to embody the character and knowledge of the institution. These chatbots assist students in navigating their college experience more effectively. Additionally, VeriCampus offers a messaging platform that aims to make education more accessible and affordable. This platform provides educational institutions with the necessary products, services, and information to facilitate student success and improve engagement across various aspects of the educational process. By focusing on personalized service at a lower cost, VeriCampus empowers schools to enhance the overall student experience.

Mash&Co is a developer of an interactive application that combines cartoons, interactive storytelling, and mini-games to create engaging edutainment for children. The app features the adventures of characters Mash and Periwinkle as they search for water in a forest, offering original stories, 2D animations, and activities designed to teach children about nature and its importance. The company focuses on content creation around culture and STEAM themes, operating under two brands: "Mash&Co" and "Super Sofia." Each brand aims to build a transmedia universe through the development of apps, games, and cartoon series. Additionally, Mash&Co has expanded its reach by establishing a twin startup in France and collaborating with companies across Europe, Asia, and the USA for co-production and distribution efforts.

Conscious Labs specializes in developing brain-computer interface (BCI) technology that allows for the collection of research-grade EEG data in real-world settings. The company creates advanced head-wearable devices designed to integrate seamlessly into headphones, earbuds, and VR and AR headsets. This technology enables electronics manufacturers and startups to embed BCI capabilities into their products, facilitating out-of-lab research and enhancing user experiences. Additionally, Conscious Labs offers expertise in sensor development and provides an innovative ionic polymer suitable for biosensors in wearable devices, thereby advancing the capabilities of biosensing technologies.

Seamless Waves is a fabless semiconductor company that specializes in designing and implementing reconfigurable RF transceivers. These advanced transceivers can sweep the frequency spectrum to identify the least occupied frequency bands, facilitating efficient communication through the appropriate wireless standards. Utilizing highly efficient RF Analog-to-Digital converters, Seamless Waves' technology ensures low power consumption, making it ideal for portable devices. In addition to its transceiver solutions, the company offers silicon-proven Analog/RF Physical Intellectual Property (IP) and virtual component models that support early system integration for clients.

Alkion BioInnovations, established in March 2017, focuses on developing innovative cannabinoid and pharmaceutical active pharmaceutical ingredient (API) production through large-scale plant tissue culture. The company utilizes proprietary semi-industrial technologies to produce natural plant active ingredients for pharmaceutical applications, aiming to create disruptive nutrition, non-cosmetic oil, and agrochemical products for both the pharmaceutical and agri-food sectors. In addition to its work in cannabinoid production, Alkion is also developing a novel plant-based high-intensity protein sweetener as a sugar replacement. The company has received multiple R&D grants and awards, including those from I-lab, I-Nov, and the European Innovation Council, recognizing its contributions to biotechnology and innovation.